✦ LIBER ✦

Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations

✍ Scribed by Kenneth E. Sherman; Russell Fleischer; Katherine Laessig; Jeffrey Murray; William Tauber; Debra Birnkrant

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 109 KB
Volume: 46
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21985

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of novel agents for the trea

Development of novel agents for the treatment of hepatitis C virus

✍ Tracy Swan; Raymond T. Chung 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB 👁 1 views

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may